EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity

Yuhang Cheng, Jiayuan Zhang, Wei Mu, Shanwei Ye, Jiali Cheng, Li Zhu, Gaoxiang Wang, Yang Cao, Dengju Li, Guang Hu, Liang Huang, Jue Wang und 1 weitere

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.02.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Yuhang Cheng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Immunot…. Hauptthemen laut MEDLINE: Dasatinib, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, Key Technologies Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The universal chimeric antigen receptor T cell (UCAR-T) immunotherapy derived from healthy donors holds great promise in pan-cancer treatment. However, UCAR-T cell therapy faces a challenge in the rapid elimination of allogeneic cells by the host immune system. To address this, we introduced a T316I mutation in the leukocyte-specific protein tyrosine kinase (LCK) locus in CAR-T cells using the cytosine base editor (CBE) system. Concurrently, we disrupted endogenous T cell receptor alpha chain (TRAC) and beta-2 microglobulin (B2M) with the CRISPR-Cas9 system, along with dasatinib to overcome host immune rejection, an Src family kinase (SFK) inhibitor. The resulting LCK mutated UCAR-T (KM UCAR-T) cells exhibited normal phenotypes in activation, proliferation, differentiation, and tumor cytotoxicity in vitro. Moreover, KM UCAR-T cells demonstrated sustained expansion in mixed lymphocyte reactions (MLR) when incubated with T cells or peripheral blood mononuclear cells (PBMCs) from HLA-mismatched donors upon dasatinib treatment. Additionally, we illustrated that KM UCAR-T cells displayed antitumor activity in a xenograft murine model and verified the expansion and cytotoxicity of KM UCAR-T over traditional UCAR-T in the presence of allogeneic PBMCs when treated with dasatinib in vivo. These findings offer a novel strategy for UCAR-T cells to resist host immune rejection and achieve sustained expansion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibReceptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesDrug Resistance, NeoplasmAnimalsHumansMiceXenograft Model Antitumor AssaysCell Line, TumorCell ProliferationProtein Kinase InhibitorsReceptors, Antigen, T-CellLymphocyte Specific Protein Tyrosine Kinase p56(lck)CRISPR-Cas SystemsMutation

Stichwörter der Autor:innen

base editingdasatinibmutant LCKtyrosine kinase inhibitoruniversal CAR-T therapy

Substanzen

DasatinibReceptors, Chimeric AntigenProtein Kinase InhibitorsReceptors, Antigen, T-CellLymphocyte Specific Protein Tyrosine Kinase p56(lck)

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuh…
  • Nanjing IASO Biotherapeutics Co., Ltd., Nanjing, Jiangsu 210000, China.
  • Nanjing IASO Biotherapeutics Co., Ltd., Nanjing, Jiangsu 210000, China. Electronic address: guang.hu@iasobio.com.
  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…

Förderung

  • Beijing Xisike Clinical Oncology Research Foundation
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • Key Technologies Research and Development Program
  • National Natural Science Foundation of China
  • Chinese Academy of Meteorological Sciences
  • National Key Research and Development Program of China
  • Innovative Research Group Project of the National Natural Science Foundation of China

Zitieren

APA

Cheng, Y., Zhang, J., Mu, W., Ye, S., Cheng, J., Zhu, L., Wang, G., Cao, Y., Li, D., Hu, G., Huang, L., Wang, J., & Zhou, J. (2025). Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.02.012

Vancouver

Cheng Y, Zhang J, Mu W, Ye S, Cheng J, Zhu L, et al. Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.02.012

BibTeX
@article{Cheng2025,
  author = {Cheng, Yuhang and Zhang, Jiayuan and Mu, Wei and Ye, Shanwei and Cheng, Jiali and Zhu, Li and Wang, Gaoxiang and Cao, Yang and Li, Dengju and Hu, Guang and Huang, Liang and Wang, Jue and Zhou, Jianfeng},
  title = {Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.02.012}
}
Kostenlos starten →